Hims & Hers names ex-FDA official Deb Autor as first policy chief

Hims & Hers Health has appointed Deb Autor as its first chief policy officer to lead public policy and government functions, ...

Novo Nordisk cuts Wegovy, Ozempic direct-to-user prices to match Eli Lilly’s Zepbound

Novo Nordisk cuts obesity drug prices to compete with Eli Lilly, offering new patient deals and nationwide access.

Hims & Hers Health stock rises after announcing $250 million buyback program

Investing.com -- Hims & Hers Health, Inc. (NYSE:HIMS) stock rose 1.5% on Monday after the health and wellness platform announced a new $250 million share repurchase program. The authorization comes ...

Novo Undercuts Lilly’s Obesity Drug Price for Cash-Pay in US

Novo Nordisk A/S is undercutting arch-rival Eli Lilly & Co. on obesity drugs for cash-pay patients, showing its willingness ...

Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2%

Hims & Hers Health (HIMS) announced on Monday an up to $250M share repurchase program of outstanding class A common stock ...

Novo Nordisk rolls out $349 Wegovy cash price ahead of plan

Novo Nordisk said on Monday it has begun selling its popular weight-loss drug Wegovy for $349 a month to cash payers, months ...